Dr Mario Sznol talks to ecancer at ASCO 2013 about long-term follow-up results from an expanded phase I study examining the effects of nivolumab in advanced melanoma.
107 patients were treated with five different doses of nivolumab. All patients had disease that worsened despite prior standard...
Published 06/13/13